Day 1 | Day 2 | Download Brochure
Recommended Short Courses*
Monday, June 14
9:00 am – 12:00 pm
(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues
2:00 pm – 5:00 pm
(SC5) Dealing with the Blood-Brain Barrier
WEDNESDAY, JUNE 16
12:30 pm Registration
1:55 Chairperson's Opening Remarks
Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D, GlaxoSmithKline
2:00 Molecular Imaging Approaches: How can it Help Drug Discovery and Development?
Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D, GlaxoSmithKline
It is critical to develop technologies that reduce attrition rates to improve the efficiency of the overall drug development process. This talk will discuss how the successful integration of molecular imaging approaches from bench to bedside would not only streamline drug development process but also allow for new opportunities in treatment management of targeted therapies including patient selection, dose optimization and optimal drug regimen.
2:30 Platform Imaging Biomakers—Applications across Pre-Clinical Drug Discovery with a Focus on Neuroscience, Oncology, Cardiovascular and Future Horizons
Thomas Bocan, Ph.D., Senior Director & Head, BioImaging Center, Pfizer Global Research & Development, Pfizer, Inc.
Imaging biomarkers allow for the pre-clinical and clinical assessment of proof of mechanism of novel drug candidates. With the development of novel PET tracers, imaging reagents and MR approaches, opportunities exist to broaden application to evolving tissue regeneration and stem cell approaches. Application of platform tools across numerous pharmacologic approaches such as AMPA potentiators, potassium channel openers, antiproliferatives and Alzheimer’s progression will be discussed.
3:00 Sponsored Presentations:The Data Deluge – An Acute Informatics Problem (Opportunity Available)
3:30 Networking Refreshment Break, Poster and Exhibit Viewing
4:30 Role for in vivo Imaging in the Development of Companion Diagnostics & Advancement of Drug Discovery
Francis Kalush, Ph.D., Network Leader, Diagnostics, Office of the Center Director, Center for Devices and Radiological Health, FDA
5:00 Novel PET Tracers as Translational Tools in Drug Discovery and Development
Dennis McCarthy, Ph.D., Director, Early Development, AstraZeneca R&D
Drug development is a time-consuming and costly endeavor. We now benefit from the discovery of new PET tracers that can be used to streamline this process. Their development requires a multidisciplinary approach combining the expertise of many fields. I will describe the discovery of new PET tracers and how, as translational tools, they can be used to expand our understanding of receptor biology and disease.
5:30 End of Day
Day 1 | Day 2 | Download Brochure